Albany, NY -- (SBWIRE) -- 12/16/2014 -- Dyslipidemia is a lipoprotein metabolism disorder characterized by abnormal amount of lipoprotein (LDL and HDL) concentrations in blood. It is usually caused by genetic factors, secondary factors or a combination of both kinds of factors. High density lipoproteins (HDL) are also known as good cholesterol and higher levels of these help reduce the risk of cardiovascular diseases. Higher levels of low density lipoproteins (LDL) or bad cholesterol are associated with the risk of heart attacks and strokes. The abnormal levels of cholesterol and triglycerides are capable of producing three forms of dyslipidemia namely, hypertriglyceridemia, hypercholesterolemia and a combination of both. Dyslipidemia is one of the major causes for the occurrence of cardiovascular diseases. Appropriate drug therapy against dyslipidemia can be selected based on the detection of varying concentrations of specific lipoproteins in the blood. The treatment approach adopted by physicians starts with non-drug interventions, which includes lifestyle modifications and exercise followed by pharmacotherapy which includes the use of lipid lowering drugs.

Browse Full Report with TOC:
http://www.transparencymarketresearch.com/dyslipidemia-market.html

The seven major classes of lipid lowering drugs used in the treatment of dyslipidemia are bile-acid sequestrants, nicotinic acid, HMG-CoA reductase inhibitors (statins), cholesterol modulators, fibric acid derivatives, cholesterol absorption inhibitors and combination products. Statins are the most widely used drugs to treat dyslipidemia. The dyslipidemia market can be segmented by the various drug classes mentioned above and by geography. The major factors influencing the growth of this market are sedentary lifestyle, higher inclination towards junk food, increasing incidence of cardiovascular diseases across the globe and associated risks. Patent expirations and high genericization may mask the growth of this market. With the patent expiration of Pfizer's Lipitor, Merck's Zocor and Bristol-Myers Squibb's Pravachol, the dyslipidemia market is expected to experience a decline in sales of branded formulations and in turn decline in overall growth of this market. Some of the major players in this market are Pfizer, Inc., Merck & Co, Inc., Bristol-Myers Squibb, Novartis AG, AstraZeneca PLC and Abbott Laboratories.

Read More Report on Pharmaceutical Market :
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Transparency Market Research
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

Enquiry Before Buying:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1535

Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/